title: Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion.
abstract: OBJECTIVE
  To investigate the outcome of intravitreal ranibizumab and/or dexamethasone implant treatment for treatment of macular edema (ME) secondary to central or branch retinal vein occlusion (CRVO or BRVO) in a clinical setting.
  
  
  METHODS
  Retrospective analysis of consecutive patients followed for at least 6 months. Data recorded included the type of occlusion, initial and final visual acuity, and number of injections.
  
  
  RESULTS
  Sixty-five patients were included, 26 had CRVO and 39 BRVO. Mean (± SD) follow-up duration was 16 (± 7.7) months. Twenty-four (36.9%) patients received ranibizumab in monotherapy, 19 patients (29.3%) dexamethasone in monotherapy, and 22 patients (33.8%) received successively both treatments. In dexamethasone-treated patients, mean (± SD) visual acuity gain was 5.8 ± 10.7 letters for BRVO and 16.8 ± 15.6 letters for CRVO. In ranibizumab-treated patients, mean (± SD) visual acuity gain was 9.2 ± 10 letters for BRVO and 18.2 ± 20.5 letters for CRVO.
  
  
  CONCLUSIONS
  Both intravitreal ranibizumab and dexamethasone intravitreal implant could be used as first-line therapy for patients with ME secondary to retinal vein occlusion.
authors.affiliation: Centre Ophtalmologique d'Imagerie et de Laser, Paris, France.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Nghiem-Buffet
authors.forename: Franck
authors.initials: F
authors.lastname: Fajnkuchen
authors.forename: Marc
authors.initials: M
authors.lastname: Buffet
authors.forename: Sandrine
authors.initials: S
authors.lastname: Ayrault
authors.forename: Anna
authors.initials: A
authors.lastname: Le Gloahec-Lorcy
authors.forename: Typhaine
authors.initials: T
authors.lastname: Grenet
authors.forename: Corinne
authors.initials: C
authors.lastname: Delahaye-Mazza
authors.forename: Gabriel
authors.initials: G
authors.lastname: Quentel
authors.forename: Salomon Y
authors.initials: SY
authors.lastname: Cohen
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage; D004343:Drug Implants; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000175:diagnosis; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone; D000069579:Ranibizumab